FDA may let Niyad's NEPHRO study close early as enrollment slows sharply.
Why Is Talphera, Inc. (TLPH) Stock Down Today?
Updated Nov 16, 2026 2:19 PM ET · Prev Close $0.91
Session Regime & Catalyst Assessment
68% Signal ConvictionTalphera, Inc. Pulling Back 4.98% on 1.20x Relative Volume
Talphera, Inc. (TLPH) is pulling back 4.98% (-$0.05) to $0.86 on 1.20x average session volume. Relative to benchmarks, TLPH is lagging the S&P 500 by -3.09%. 14-day RSI stands at 26.1, keeping momentum in a oversold regime.
FDA may let Niyad's NEPHRO study close early as enrollment slows sharply.
Price ($0.86) trades relative to 20-day SMA ($1.04) and 50-day SMA ($1.10).
Market & Sector Relative Strength
TLPH lagging the S&P 500 by -3.09%Recent TLPH Catalyst Headlines
Verified WireTalphera Nasdaq Tlph is seeking the U.S. Food and Drug Administration s agreement to end enrollment in its Niyad study by Dec. 31, 2026, after a recent slowdown in recruiting critically ill patients, executives said on t
TLPH on Thursday reported a loss of 4 million in its third quarter.On a per-share basis, the San Mateo, California-based company said it had a loss of 5 cents.
Talphera, Inc. Nasdaq TLPH Talphera , a specialty pharmaceutical company developing nafamostat as a regional anticoagulant for use in continuous renal replacement therapy CRRT , today announced financial results for the
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.83 (session support) for directional breakout confirmation.
Technical Regime (TLPH)
BEARISH MA TRENDRetail & Crowd Sentiment
Very BullishA bullish StockTwits user is looking forward to $TLPH's Q3 2026 report summary, expressing optimism for a resolution by the end of the year.
About Talphera, Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and Ltx-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Get Instant TLPH Catalyst Alerts
Receive an email alert when TLPH triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversTLPH Session & Catalyst FAQ
Why is TLPH stock down today?
Talphera, Inc. (TLPH) is pulling back 4.98% (-$0.05) to $0.86 on 1.20x average session volume. Relative to benchmarks, TLPH is lagging the S&P 500 by -3.09%. 14-day RSI stands at 26.1, keeping momentum in a oversold regime.
Is TLPH stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.20x relative volume (moderate participation). Our multi-factor model currently rates TLPH as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the TLPH Buy or Sell Decision Brief →
What is TLPH's intrinsic value and expected trading range?
At $0.86, TLPH's modeled 1-to-3 session range is $0.81 – $0.91, with a key inflection level at $0.83 (session support). Compare current price against multi-year cash flow projections in the TLPH Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for TLPH?
RSI at 26.1 indicates oversold conditions — watch for mean-reversion support. TLPH trades at $0.86 relative to its 20-day SMA ($1.04) and 50-day SMA ($1.10), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.